https://www.selleckchem.com/pr....oducts/resiquimod.ht
4% vs 34.8%, p less then 0.001) and had medication overuse headache less frequently (55.1% vs. 63.0%, p = 0.03). Conclusion Triptans were not used by three-quartersof CM patients. Nonuse of triptans was not justified by tolerability, frequency of contraindications, or frequency of VRF. Expert opinion In the present study, we evaluated causes and consequences of the nonuse of triptans in CM sufferers. We analyzed frequency of triptan use in CM patients. We compared, between triptan users and triptan naïve patients, the presence of con
Like
Comment
Share
